Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 4/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | GIPR | P48546 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | NMT2 | O60551 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.45 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.44 |
| ▸ | CALCR | P30988 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509016 | 0.97 | NPY4R (0.45) | GLP1RGCGRGIPROPRL1ECE1 | |
| SCHEMBL16508981 | 0.97 | NPY4R (0.45) | GLP1RGCGRGIPROPRL1ECE1 | |
| SCHEMBL16509107 | 0.95 | TLR2 (0.52) | GLP1RGCGRGIPROPRL1TFPI | |
| SCHEMBL16509013 | 0.92 | NPY4R (0.49) | GLP1RGCGRGIPRTLR2NMT2 | |
| SCHEMBL16509067 | 0.91 | TLR2 (0.54) | TLR2NMT2NMT1 | |
| SCHEMBL16509119 | 0.89 | NPY4R (0.51) | GLP1RGCGRGIPRRXFP1 | |
| SCHEMBL16509029 | 0.89 | NPY4R (0.51) | GLP1RGCGRGIPRRXFP1 | |
| SCHEMBL16509060 | 0.87 | NPY4R (0.53) | TLR2NMT2NMT1 | |
| SCHEMBL16508064 | 0.87 | TFPI (0.49) | GLP1RGCGRGIPROPRL1TFPI | |
| SCHEMBL16507754 | 0.86 | OPRL1 (0.46) | GLP1RGCGRGIPROPRL1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | GLP1R 154/4885GCGR 131/4885GIPR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.